Western blotting showed that ALW-II-41-27 reduced the levels of pY772-EphA2, pS897-EphA2, p-Shp2, and p-Erk-1/2 in the NPC cells expressing EphA2-WT in a dose-dependent manner (Fig. 6a), indicating that ALW-II-41-27 inhibits the activation of Y772-EphA2 and its downstream Shp2/Erk-1/2 signaling. The gene discussed is PTPN11; the disease is nasopharyngeal carcinoma.